MOLECULAR PARTNERS TO PRESENT AT THE COWEN AND COMPANY 38th ANNUAL HEALTHCARE CONFERENCE Dienstag, 06. März 2018 - 22:18
| Media Release (PDF) | ||||||||||||||||
MOLECULAR PARTNERS TO PRESENT AT | ||||||||||||||||
Zurich-Schlieren, March 06, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced that it will present at the Cowen and Company 38th Annual Healthcare Conference on Tuesday, March 13, 2018 at 8:00 ET (2:00 PM CET).
The presentation, followed by a breakout session, will be hosted by Dr. Patrick Amstutz, CEO of Molecular Partners and Dr. Michael Stumpp, CSO of the company.
The presentation will be webcast live and can be accessed on the day via this link. A copy of the presentation handout as well as a replay of the webcast will be made available on the company's website www.molecularpartners.com under the Investors section. The replay will be available for 90 days following the presentation. | ||||||||||||||||
About Molecular Partners AG Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.
For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.
For further details, please contact:
*DARPin® is a registered trademark owned by Molecular Partners AG. |